NeutroSpec Pulled From The Market
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA "reconsidered" the risk/benefit balance for Mallinckrodt/Palatin Technologies' appendicitis imaging agent, which has been associated with cardiopulmonary events.
You may also be interested in...
NeutroSpec Promos Tout Broad, Unsupported Indications, FDA Chides
The withdrawn imaging agent is cited for violations made during the 2005 American Pharmaceutical Association annual meeting.
NeutroSpec Promos Tout Broad, Unsupported Indications, FDA Chides
The withdrawn imaging agent is cited for violations made during the 2005 American Pharmaceutical Association annual meeting.
“Dear Doctor” Letter Cautions About Cardiopulmonary Events With NeutroSpec
Letter from Mallinckrodt and Palatin alerts healthcare providers to serious cardiopulmonary events that may occur within minutes of injection with the imaging agent.